Structures by: Bhardwaj R. M.
Total: 95
Olanzapine propan-1-ol
C17H20N4S,C3H8O
CrystEngComm (2018) 20, 28 3947
a=10.217(3)Å b=13.069(4)Å c=14.918(5)Å
α=90.00° β=95.342(7)° γ=90.00°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0093(3)Å b=22.8207(8)Å c=10.4016(4)Å
α=90° β=91.416(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1345(7)Å b=23.048(3)Å c=7.4330(8)Å
α=90° β=90.449(6)° γ=90°
30:70 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.72(Br),0.28(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.2017(6)Å b=22.3376(13)Å c=10.5639(6)Å
α=90° β=90.157(3)° γ=90°
Alpha lipoicacid nicotinamide co-crystal
C8H14O2S2,C6H6N2O
CrystEngComm (2014) 16, 26 5769
a=26.292(2)Å b=5.2948(4)Å c=34.158(3)Å
α=90.00° β=90.598(4)° γ=90.00°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0604(18)Å b=22.876(4)Å c=10.4041(19)Å
α=90° β=91.741(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=9.9973(13)Å b=22.788(3)Å c=10.4078(14)Å
α=90° β=91.2430(10)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1160(12)Å b=22.916(4)Å c=7.3818(13)Å
α=90° β=91.415(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1234(14)Å b=22.966(4)Å c=7.3986(14)Å
α=90° β=91.146(2)° γ=90°
(+-)-4'-methylmethcathinone hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1264(14)Å b=22.986(5)Å c=7.4072(14)Å
α=90° β=90.974(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1314(14)Å b=23.013(5)Å c=7.4180(15)Å
α=90° β=90.803(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1365(14)Å b=23.041(5)Å c=7.4304(15)Å
α=90° β=90.628(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=5.7804(4)Å b=19.7971(14)Å c=10.5967(6)Å
α=90° β=100.841(3)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=10.8355(19)Å b=10.2030(17)Å c=11.5425(19)Å
α=90° β=111.839(8)° γ=90°
60:40 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.4(Br),0.6(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.1409(11)Å b=22.488(3)Å c=10.4979(11)Å
α=90° β=90.359(8)° γ=90°
70:30 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16Br0.30Cl0.70N1O1
CrystEngComm (2014) 16, 26 5827
a=10.1012(5)Å b=22.5506(12)Å c=10.4737(5)Å
α=90° β=90.441(3)° γ=90°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
Butylparaben isonicotinamide
C11H14O3,C6H6N2O
Acta Crystallographica Section E (2016) 72, 1 53-55
a=5.6257(6)Å b=9.8661(11)Å c=14.3979(15)Å
α=90.834(7)° β=91.431(7)° γ=91.645(7)°
Amoxapine acetate acetic acid monosolvate cyclohexane hemisolvate
C17H17ClN3O,C2H3O2,C2H4O2,0.5(C6H12)
Acta Crystallographica Section E (2015) 71, 2 139-141
a=21.0726(12)Å b=6.0393(3)Å c=18.6087(10)Å
α=90.00° β=92.096(2)° γ=90.00°
Loxapine succinate monohydrate
2(C18H19ClN3O),C4H4O42,C4H6O4,2(H2O)
Acta Crystallographica Section C (2013) 69, 11 1273-1278
a=9.4171(6)Å b=9.7604(7)Å c=13.7949(9)Å
α=74.708(2)° β=86.102(2)° γ=65.518(2)°
Loxapine succinate
C18H19ClN3O,C4H5O4
Acta Crystallographica Section C (2013) 69, 11 1273-1278
a=36.1824(5)Å b=7.08622(14)Å c=18.7690(2)Å
α=90° β=113.8402(10)° γ=90°
6-Methyl-1,3,5-triazine-2,4-diamine butane-1,4-diol monosolvate
C4H7N5,C4H10O2
Acta Crystallographica Section E (2012) 68, 12 o3377
a=5.8755(3)Å b=9.0515(5)Å c=10.7607(5)Å
α=87.911(3)° β=74.346(3)° γ=83.550(3)°
Olanzapine propan-2-ol disolvate
C17H20N4S,2(C3H8O)
Acta Crystallographica Section E (2013) 69, 5 o752-o753
a=9.9621(5)Å b=10.8702(6)Å c=12.2298(7)Å
α=70.421(2)° β=74.560(2)° γ=77.296(2)°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=19.4305(17)Å b=11.3245(11)Å c=9.1511(9)Å
α=90° β=95.302(5)° γ=90°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.2116(11)Å b=11.5104(14)Å c=11.8746(18)Å
α=102.001(10)° β=105.368(11)° γ=102.349(9)°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=7.7119(14)Å b=8.9111(17)Å c=14.617(2)Å
α=81.906(13)° β=78.799(14)° γ=75.258(15)°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=10.7270(3)Å b=14.4711(5)Å c=12.7050(4)Å
α=90° β=107.1120(17)° γ=90°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.134(2)Å b=12.620(4)Å c=18.059(3)Å
α=86.707(19)° β=100.094(15)° γ=83.303(19)°
TGF Beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.5537(2)Å b=11.3718(4)Å c=11.5674(5)Å
α=65.784(3)° β=105.495(3)° γ=77.315(2)°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=18.9981(11)Å b=9.8532(6)Å c=21.8829(13)Å
α=90° β=113.219(3)° γ=90°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=11.3011(3)Å b=20.8473(5)Å c=8.10637(17)Å
α=90° β=98.879(2)° γ=90°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=27.938(4)Å b=8.0817(7)Å c=22.004(3)Å
α=90° β=133.55(3)° γ=90°
4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=27.654(13)Å b=8.108(8)Å c=21.934(11)Å
α=90° β=133.41(8)° γ=90°
C22H19N5OCH4O
C22H19N5OCH4O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0458(4)Å b=22.6024(10)Å c=11.2097(5)Å
α=90° β=106.274(2)° γ=90°
TGF Beta
C22H19N5OC2H6O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0820(4)Å b=9.2580(4)Å c=15.5250(7)Å
α=73.338(2)° β=89.974(2)° γ=84.594(2)°
TGF Beta
C22H19N5OC3H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=7.7720(11)Å b=11.8319(18)Å c=12.8267(17)Å
α=89.030(9)° β=74.293(8)° γ=82.225(10)°
TGF Beta
C26H29N5O2
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1145(8)Å b=12.0611(13)Å c=12.5401(13)Å
α=88.454(5)° β=79.842(4)° γ=76.813(5)°
TGF beta
C22H19N5OC4H10O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1676(2)Å b=11.9112(3)Å c=12.7014(3)Å
α=89.4745(11)° β=81.2360(14)° γ=75.9211(11)°
TGF Beta
C22H19N5O,2(C4H8O2)
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=10.6011(8)Å b=11.6654(9)Å c=12.5667(9)Å
α=69.035(3)° β=86.603(2)° γ=81.573(2)°
TGF beta
C22H19N5O,C4H9NO
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.6946(4)Å b=10.9640(4)Å c=12.9344(5)Å
α=77.7370(16)° β=88.5612(17)° γ=79.1558(19)°
TGF Beta
C22H19N5O,C4H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.3929(7)Å b=11.7452(9)Å c=12.0347(10)Å
α=92.483(3)° β=106.415(4)° γ=97.071(4)°
TGF beta
C22H19N5O,CH2Cl2
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.4961(8)Å b=10.3766(10)Å c=12.7043(12)Å
α=103.239(5)° β=91.904(5)° γ=94.505(5)°
C22H19N5O,C4H10O
C22H19N5O,C4H10O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1840(8)Å b=12.0219(12)Å c=12.6533(12)Å
α=89.543(6)° β=81.238(6)° γ=75.349(6)°
C22H19N5O,C2H6O
C22H19N5O,C2H6O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1100(4)Å b=11.6569(6)Å c=12.7599(6)Å
α=90.026(4)° β=99.248(4)° γ=101.238(4)°
C22H19N5O,C2H4O2
C22H19N5O,C2H4O2
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.5331(11)Å b=10.9792(13)Å c=11.6291(17)Å
α=66.668(12)° β=65.944(8)° γ=78.915(9)°
C22H19N5OC3H8O
C22H19N5OC3H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0480(8)Å b=11.4825(13)Å c=12.8727(13)Å
α=89.280(7)° β=80.416(7)° γ=79.313(7)°
TGF beta
C22H19N5O,C5H10O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.5823(11)Å b=11.0257(18)Å c=12.7778(16)Å
α=101.925(12)° β=92.429(11)° γ=97.579(12)°
TGF beta
C22H19N5OC4H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=12.1495(14)Å b=8.4511(9)Å c=20.111(2)Å
α=90° β=93.551(7)° γ=90°
TGF beta
C22H19N5O,C5H9NO
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.9660(6)Å b=33.730(2)Å c=7.3404(5)Å
α=90° β=106.892(2)° γ=90°
3,4,5-trihydroxybenzoic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=25.685(3)Å b=4.9273(5)Å c=11.2508(12)Å
α=90° β=106.234(2)° γ=90°
Gallic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=5.2303(1)Å b=5.26495(12)Å c=24.7927(4)Å
α=90° β=102.1116(17)° γ=90°
Gallic acid
C7H6O5,H2O
Crystal growth & design (2013) 13, 1 19-23
a=7.60719(9)Å b=3.64133(4)Å c=26.7915(4)Å
α=90° β=98.4212(11)° γ=90°
Gallic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=7.31853(19)Å b=8.2536(2)Å c=11.7148(3)Å
α=100.4719(12)° β=90.2335(17)° γ=90.9844(17)°
Olanzapine
C17H20N4S1
Crystal Growth & Design (2013) 13, 4 1602
a=10.3411(13)Å b=14.521(2)Å c=10.5314(14)Å
α=90.00° β=100.291(4)° γ=90.00°
Olanzapine
C17H20N4S1
Crystal Growth & Design (2013) 13, 4 1602
a=9.8544(14)Å b=16.314(2)Å c=9.9754(12)Å
α=90.00° β=98.304(8)° γ=90.00°
Olanzapine 2-butoxyethanol
C17H20N4S1,(C6H14O2)
Crystal Growth & Design (2013) 13, 4 1602
a=10.4420(10)Å b=17.7328(15)Å c=15.5165(13)Å
α=90.00° β=126.279(5)° γ=90.00°
Olanzapine 2,2,2-trifluoroethanol
C17H20N4S1,2(C2F3O1H3)
Crystal Growth & Design (2013) 13, 4 1602
a=12.7244(9)Å b=11.7538(8)Å c=16.0067(11)Å
α=90.00° β=94.782(2)° γ=90.00°
Olanzapine acetic acid
C17H20N4S1(C2O2H4)
Crystal Growth & Design (2013) 13, 4 1602
a=10.0427(11)Å b=12.7430(13)Å c=14.3886(15)Å
α=90.00° β=92.436(4)° γ=90.00°
Olanzapine ethyleneglycol
C17H20N4S1,(C2H6O2)
Crystal Growth & Design (2013) 13, 4 1602
a=9.8393(16)Å b=13.278(2)Å c=14.588(2)Å
α=90.00° β=96.328(7)° γ=90.00°
Olanzapine ethanol
C17H20N4S1,C2H6O1
Crystal Growth & Design (2013) 13, 4 1602
a=10.3489(18)Å b=13.003(2)Å c=13.870(2)Å
α=90.00° β=92.496(6)° γ=90.00°
Olanzapine TBMe hydrate
C17H20N4S1,(C5H12O1),2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.2070(1)Å b=12.2211(9)Å c=14.550(1)Å
α=90.00° β=109.239(3)° γ=90.00°
Olanzapine t-butanol hydrate
2(C17H20N4S1),2(C4H10O1),5(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.2491(9)Å b=12.3838(8)Å c=27.1418(17)Å
α=90.00° β=99.052(2)° γ=90.00°
Olanzapine 3-methyl 1-butanol hydrate
2(C17H20N4S1),2(C5H12O1),2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=12.3420(17)Å b=13.3559(18)Å c=14.630(2)Å
α=105.883(6)° β=90.290(6)° γ=92.005(6)°
Olanzapine N,N dimethylforamide hydrate
2(C17H20N4S),(C3H7NO1)2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.9885(9)Å b=12.7558(7)Å c=19.8567(12)Å
α=90.00° β=93.348(2)° γ=90.00°
Olanzapine 1.4-butanediol hydrate
2(C17H20N4S1),(C4O2H10),2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=12.2637(11)Å b=14.1146(10)Å c=14.1783(12)Å
α=63.985(3)° β=65.649(4)° γ=65.437(4)°
Olanzapine-2-pentanol hydrate
C17H20N4S1,C5H12O1,H2O
Crystal Growth & Design (2013) 13, 4 1602
a=13.4466(10)Å b=12.3833(9)Å c=14.5522(9)Å
α=90.00° β=104.839(2)° γ=90.00°
Olanzapine N,N,N-triethylamine hydrate
(C17H20N4S),0.5(C6H15N)2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=14.8170(10)Å b=12.6230(10)Å c=14.4610(10)Å
α=90.00° β=113.36(2)° γ=90.00°
Olanzapine pyridine hydrate
2(C17H20N4S1),(C5H5N)2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=14.8824(7)Å b=12.7289(7)Å c=20.3218(11)Å
α=90.00° β=93.465(2)° γ=90.00°
Olanzapine 1-butanol hydrate
C17H20N4S1,0.5(C4H10O1),H2O1
Crystal Growth & Design (2013) 13, 4 1602
a=24.575(6)Å b=12.429(3)Å c=15.006(3)Å
α=90.00° β=125.255(7)° γ=90.00°
Olanzapine nitromethane hydrate
C17H20N4S1,0.5(CH3NO2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.352(3)Å b=12.3706(13)Å c=15.0182(18)Å
α=90.00° β=125.531(5)° γ=90.00°
Olanzapine 1,2-dimethoxyethane hydrate
(C17H20N4s1),0.5(C4H10O2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.4675(13)Å b=12.2298(8)Å c=15.1073(8)Å
α=90.00° β=125.675(2)° γ=90.00°
Olanzapine methanol
C17H20N4S1(C1H4O1)
Crystal Growth & Design (2013) 13, 4 1602
a=10.1493(9)Å b=12.2895(10)Å c=14.0944(13)Å
α=90.00° β=91.905(5)° γ=90.00°
Olanzapine dihydrate
C17H20N4S1,2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=9.846(2)Å b=12.672(3)Å c=14.384(3)Å
α=90.00° β=92.724(9)° γ=90.00°
Olanzapine dichloromethane
2(C17H20N4S1),1(CH2Cl2)
Crystal Growth & Design (2013) 13, 4 1602
a=9.6671(15)Å b=11.5070(17)Å c=16.697(2)Å
α=103.991(6)° β=96.989(6)° γ=99.825(6)°
Olanzapine 1,4-dioxan hydrate
C17H20N4S,0.5(C4H8O2),(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.447(3)Å b=12.5660(16)Å c=14.9591(19)Å
α=90.00° β=125.421(5)° γ=90.00°
Olanzapine acetonitrile hydrate
(C17H20N4S1),(C2H3N1),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.381(2)Å b=12.3856(9)Å c=15.0565(14)Å
α=90.00° β=125.321(7)° γ=90.00°
Olanzpaine tetrahydrofuran hydrate
C17H20N4S,0.5(C4H8O),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.2355(10)Å b=12.5913(5)Å c=15.0767(6)Å
α=90.00° β=124.9990(10)° γ=90.00°
Olanzapine acetone hydrate
C17H20N4S1,0.5(C3O1H6),(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.226(2)Å b=12.5269(12)Å c=15.0737(15)Å
α=90.00° β=124.976(4)° γ=90.00°
Olanzapine methylacetate hydrate
C17H20N4S1,0.5(C3H6O2),H2O1
Crystal Growth & Design (2013) 13, 4 1602
a=24.899(4)Å b=12.5316(19)Å c=15.243(2)Å
α=90.00° β=126.990(5)° γ=90.00°
Olanzapine 1,2 propanediol hydrate
C17H20N4S1,(C3H8O2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.704(2)Å b=12.1883(10)Å c=15.1242(12)Å
α=90.00° β=125.206(3)° γ=90.00°
Olanzapine 1-propanol hydrate
C17H20N4S1,0.5(C3H8O1),(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.4748(13)Å b=12.3515(6)Å c=15.1109(8)Å
α=90.00° β=125.6490(10)° γ=90.00°
Olanzapine higher hydrate
C17H20N4S1,2.5(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.940(6)Å b=12.156(3)Å c=14.867(3)Å
α=90.00° β=124.928(6)° γ=90.00°
1,3,5-trihydroxybenzene
C6H6O3
Crystal growth & design (2013) 13, 9 4071-4083
a=12.1207(6)Å b=3.80651(13)Å c=13.1647(6)Å
α=90° β=115.478(6)° γ=90°
Pyrogallol_tetartohydrate
4(C6H6O3),H2O
Crystal growth & design (2013) 13, 9 4071-4083
a=24.6058(6)Å b=24.6058(6)Å c=3.8524(3)Å
α=90° β=90° γ=90°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.2599(3)Å b=19.6072(14)Å c=12.6913(6)Å
α=90° β=116.545(2)° γ=90°
C22H19N5O,H2O
C22H19N5O,H2O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.0505(7)Å b=11.3624(9)Å c=19.1323(16)Å
α=90° β=94.954(3)° γ=90°
TGF Beta
C22H19N5OC5H12O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0879(6)Å b=12.3578(9)Å c=12.8909(9)Å
α=85.722(3)° β=77.875(3)° γ=74.707(3)°
TGF beta
C22H19N5O,0.5(C4H8O2),H2O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=7.7332(3)Å b=11.4956(4)Å c=12.1986(4)Å
α=85.299(2)° β=84.505(2)° γ=85.518(2)°
C22H19N5O,C4H8O
C22H19N5O,C4H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.8533(7)Å b=11.2079(6)Å c=11.5743(6)Å
α=101.869(2)° β=105.813(2)° γ=105.560(2)°
Olanzapine 2-methoxyethanol hydrate
C17H20N4S,0.5(C3H8O2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=25.0869(8)Å b=12.3821(4)Å c=15.1983(5)Å
α=90.00° β=126.8720(10)° γ=90.00°